KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gilead Sciences (GILD) Revenue (2016 - 2025)

Gilead Sciences (GILD) has disclosed Revenue for 17 consecutive years, with $7.9 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Revenue rose 4.7% year-over-year to $7.9 billion, compared with a TTM value of $29.4 billion through Dec 2025, up 2.4%, and an annual FY2025 reading of $29.4 billion, up 2.4% over the prior year.
  • Revenue was $7.9 billion for Q4 2025 at Gilead Sciences, up from $7.8 billion in the prior quarter.
  • Across five years, Revenue topped out at $7.9 billion in Q4 2025 and bottomed at $6.2 billion in Q2 2021.
  • Average Revenue over 5 years is $7.0 billion, with a median of $7.0 billion recorded in 2022.
  • The sharpest move saw Revenue grew 20.88% in 2021, then fell 5.11% in 2022.
  • Year by year, Revenue stood at $7.2 billion in 2021, then increased by 2.0% to $7.4 billion in 2022, then decreased by 3.72% to $7.1 billion in 2023, then rose by 6.4% to $7.6 billion in 2024, then increased by 4.7% to $7.9 billion in 2025.
  • Business Quant data shows Revenue for GILD at $7.9 billion in Q4 2025, $7.8 billion in Q3 2025, and $7.1 billion in Q2 2025.